€ \$08 Rec'd PCT/PTO

Unknown

1 4 MAY 2001

Form PTO-1449 U.S. Departit of Commer Patent and Ademark Office ATTY. DOCKET NO. at of Commerce IVD 1087 PCT/FR99/02761 INFORMATION DISCLOSURE STATEMENT APPLICANT CASELLAS, Pierre and DEROCQ, Jean-Marie **BY APPLICANT** FILING DATE GROUP

(Use several sheets if necessary)

HE DATENT DOCUMENTS

Herewith

Examiner Document Number Date Name Class Subclass Filing Date						
Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
					÷	
			-			
	Document Number	· · · · · · · · · · · · · · · · · · ·				

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No	
 						165	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BTO	Levy, A Psychosomatic Approach to the Management Of Recalcitrant Dermatoses, 4(6), Nov. 1963, 334-337.					
	Ormfa et al., Ricerche preliminari clinico-psicologiche su di un nuovo derivato benzodiazepinico (Nobrium) in dermatologia, 45(5), May 1970, 325-339.					
	Carayon et al., Involvement of Peripheral Benzodiazepine Receptors in the Protection of Hematopoietic Cells Against Oxygen Radical Damage, 87(8), April 1996, 3170-3178.					
Br	Boh et al., Role of Reactive Oxygen Species in Dermatologic Diseases, 14(4), July 1996, 343-352.					
EXAMINER	DATE CONSIDERED 7/17/01 [Mitiglif citation considered, whether or not citation is in conformance with MPER 600: Drow line through citation if not in					

conformance and not considered. Include copyof this form with next communication to applicant.